Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.
Follow HOWL
Werewolf Therapeutics, Inc. (HOWL) EV/Sales
As of 16 October 2026, Werewolf Therapeutics, Inc. (HOWL) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from −4.3× (March 2025) to 10.4× (April 2024); the current reading is higher than 88% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −2.2× | — |
| FY2023 | 3.2× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.7× | — |
| Jun 2024 | −0.8× | — |
| Mar 2024 | 9.5× | 197.18% |
| Dec 2023 | 3.2× | — |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IBIO iBio, Inc. compare | −9.7× |
| CRBU Caribou Biosciences, Inc. compare | −6.5× |
| ACET Adicet Bio, Inc. compare | −1.8× |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| LONA LeonaBio, Inc. compare | n/m |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| ELTX Elicio Therapeutics, Inc. compare | 0.6× |
| HOWL Werewolf Therapeutics, Inc. | 1.9× |
| HYPD Hyperion DeFi, Inc. compare | 27.9× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)